Inclusion Criteria:~* Gradual and progressive change in memory function reported by the participant or
informant for â‰¥6 months.~* Meet florbetapir F18 PET scan criteria.~* A Clinical Dementia Rating (CDR)-Global
Score of 0.5 or 1.~* Must consent to apolipoprotein E (ApoE) genotyping~* Must have a mini mental state
examination (MMSE) score between 20 and 30~* Have a study partner who will provide written informed consent to
participate, is in frequent contact with the participant (defined as at least 10 hours per week), and will
accompany the participant to study visits or be available by telephone at designated times.~* Have adequate
literacy, vision, and hearing for neuropsychological testing in the opinion of the investigator at the time of
screening.~* Women not of childbearing potential may participate~
